Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

NASDAQ:GLMD opened at $0.38 on Tuesday. The firm has a market cap of $1.92 million, a P/E ratio of -0.12 and a beta of 0.87. Galmed Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $7.80. The firm has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.39.

Institutional Trading of Galmed Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Walleye Capital LLC bought a new stake in shares of Galmed Pharmaceuticals in the third quarter worth approximately $155,000. Millennium Management LLC grew its stake in shares of Galmed Pharmaceuticals by 218.4% in the fourth quarter. Millennium Management LLC now owns 149,217 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 102,351 shares during the period. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Galmed Pharmaceuticals in the first quarter worth approximately $42,000. Finally, Raymond James Financial Services Advisors Inc. grew its stake in shares of Galmed Pharmaceuticals by 158.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 63,310 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 38,856 shares during the period. 76.14% of the stock is currently owned by institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.